Resilience in Vaccine Innovation

This chapter examines the preparation and optimism of biotech companies in late 2019 as they faced an emerging pandemic threat. It contrasts the commitment of researchers to vaccine development with the broader pharmaceutical industry's cautious approach due to financial concerns, while also highlighting the significant advancements in mRNA technology. The discussion delves into the complexities of the U.S. healthcare system and the emotional and psychological toll on vaccine developers amidst public scrutiny.